PMID: 7519586Aug 1, 1994Paper

Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers

International Journal of Cancer. Journal International Du Cancer
D J FlavellS U Flavell

Abstract

A SCID mouse model of human T-ALL has been used to determine the in vivo therapeutic efficacy of two anti-CD7-saporin immunotoxins constructed with either a hindered (HB2-SMPT-Sap) or non-hindered (HB2-SPDP-Sap) disulphide bond between antibody and saporin. Groups of 10 SCID mice were injected intravenously (i.v.) with 2 x 10(6) human T-ALL HSB-2 cells followed seven days later by i.v. injection with either a single dose or with 3 doses of HB2-SPDP-Sap or HB2-SMPT-Sap given on alternate days. Control groups received equivalent sham injections of PBS or molar equivalent amounts of unconjugated HB2 antibody+saporin. Animals receiving a single dose of HB2-SMPT-Sap showed better survival than animals receiving a single dose of HB2-SPDP-Sap but the difference was not shown to be significant by log-rank analysis. When given as a triple dose both immunotoxins performed similarly. Comparison of single-dose with triple-dose IT therapy revealed that the therapeutic effect of a triple dose of HB2-SPDP-Sap was significantly better than that of single dose, but this was not the case with HB2-SMPT-Sap. Pharmacokinetic studies of HB2-SPDP-Sap and HB2-SMPT-Sap in normal and HSB-2 leukaemia bearing SCID mice failed to reveal any difference in c...Continue Reading

Citations

Jun 6, 2000·Advanced Drug Delivery Reviews·I Pastan, R J Kreitman
Nov 10, 2011·Toxins·Letizia PolitoAndrea Bolognesi
Oct 10, 2013·Toxins·Letizia PolitoAndrea Bolognesi
Jun 7, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Iring HeislerHendrik Fuchs
Feb 14, 2018·Toxins·Francesco GiansantiRodolfo Ippoliti

❮ Previous
Next ❯

Related Concepts